Renal Medullary Carcinoma

• CLINICAL_TRIALS research · 2026-04-24
  Clinical Trial Update: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... [Phase 2]

  A Phase 2 clinical trial (SMART) is assessing sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors and is current…

• CLINICAL_TRIALS research · 2026-04-15
  Clinical Trial Update: Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla [Phase 2]

  Phase II clinical trial update for an immunotherapy in carcinomas arising from the renal medulla. The study is currently active but not recr…

• CLINICAL_TRIALS research · 2026-03-02
  Clinical Trial Update: Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma [Phase 2]

  Phase II clinical trial update for sacituzumab govitecan in SMARCB1-deficient renal medullary carcinoma; the study is not yet recruiting.

• CLINICAL_TRIALS research · 2026-01-09
  Clinical Trial Update: Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer [Phase 2]

  A Phase 2 clinical trial update evaluating ixazomib, gemcitabine, and doxorubicin in locally advanced or metastatic renal cell carcinoma, in…

• CLINICAL_TRIALS research · 2025-09-09
  Clinical Trial Update: Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma [Phase 2]

  A Phase 2 trial is evaluating pembrolizumab plus enfortumab vedotin for collecting duct carcinoma and renal medullary carcinoma, currently r…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.